{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:49:28Z","timestamp":1794019768662,"version":"4.8.0"},"reference-count":30,"publisher":"American Association for Cancer Research (AACR)","issue":"4","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune checkpoint therapies exhibit impressive efficacy in some patients with melanoma or lung cancer, but the lack of response in most cases presses the question of how general efficacy can be improved. In addressing this question, we generated a preclinical tumor model to study anti-PD-1 resistance by in vivo passaging of Kras-mutated, p53-deficient murine lung cancer cells (p53R172H\u0394g\/+K-rasLA1\/+) in a syngeneic host exposed to repetitive dosing with anti-mouse PD-1 antibodies. PD-L1 (CD274) expression did not differ between the resistant and parental tumor cells. However, the expression of important molecules in the antigen presentation pathway, including MHC class I and II, as well as \u03b22-microglobulin, were significantly downregulated in the anti-PD-1\u2013resistant tumors compared with parental tumors. Resistant tumors also contained fewer CD8+ (CD8\u03b1) and CD4+ tumor-infiltrating lymphocytes and reduced production of IFN\u03b3. Localized radiotherapy induced IFN\u03b2 production, thereby elevating MHC class I expression on both parental and resistant tumor cells and restoring the responsiveness of resistant tumors to anti-PD-1 therapy. Conversely, blockade of type I IFN signaling abolished the effect of radiosensitization in this setting. Collectively, these results identify a mechanism of PD-1 resistance and demonstrate that adjuvant radiotherapy can overcome resistance. These findings have immediate clinical implications for extending the efficacy of anti-PD-1 immune checkpoint therapy in patients. Cancer Res; 77(4); 839\u201350. \u00a92016 AACR.<\/jats:p>","DOI":"10.1158\/0008-5472.can-15-3142","type":"journal-article","created":{"date-parts":[[2016,11,7]],"date-time":"2016-11-07T23:08:48Z","timestamp":1478560128000},"page":"839-850","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":228,"title":["Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy"],"prefix":"10.1158","volume":"77","author":[{"given":"Xiaohong","family":"Wang","sequence":"first","affiliation":[{"name":"1Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Schoenhals","sequence":"additional","affiliation":[{"name":"1Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailin","family":"Li","sequence":"additional","affiliation":[{"name":"1Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Valdecanas","sequence":"additional","affiliation":[{"name":"1Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiping","family":"Ye","sequence":"additional","affiliation":[{"name":"2Department of Otolaryngology Head and Neck Surgery, The Affiliated Baiyun Hospital of Guiyang Medical University, Guiyang Medical University, Guiyang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenglin","family":"Zang","sequence":"additional","affiliation":[{"name":"3Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Tang","sequence":"additional","affiliation":[{"name":"4Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Tang","sequence":"additional","affiliation":[{"name":"5Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Gong","family":"Liu","sequence":"additional","affiliation":[{"name":"6Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuping","family":"Liu","sequence":"additional","affiliation":[{"name":"6Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Krishnan","sequence":"additional","affiliation":[{"name":"4Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Allison","sequence":"additional","affiliation":[{"name":"7Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padmanee","family":"Sharma","sequence":"additional","affiliation":[{"name":"8Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hwu","sequence":"additional","affiliation":[{"name":"9Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritsuko","family":"Komaki","sequence":"additional","affiliation":[{"name":"4Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem W.","family":"Overwijk","sequence":"additional","affiliation":[{"name":"10Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Gomez","sequence":"additional","affiliation":[{"name":"4Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe Y.","family":"Chang","sequence":"additional","affiliation":[{"name":"4Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Hahn","sequence":"additional","affiliation":[{"name":"4Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Angelica","family":"Cortez","sequence":"additional","affiliation":[{"name":"1Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Welsh","sequence":"additional","affiliation":[{"name":"4Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2017,2,14]]},"reference":[{"key":"2022061706163379300_bib1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","article-title":"Targeting the PD-1\/B7-H1(PD-L1) pathway to activate anti-tumor immunity","volume":"24","author":"Topalian","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"2022061706163379300_bib2","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"2022061706163379300_bib3","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"2022061706163379300_bib4","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/PPO.0000000000000063","article-title":"B7-H1\/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction","volume":"20","author":"Gettinger","year":"2014","journal-title":"Cancer J"},{"key":"2022061706163379300_bib5","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"2022061706163379300_bib6","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"2022061706163379300_bib7","doi-asserted-by":"crossref","first-page":"e1002726","DOI":"10.1080\/2162402X.2014.1002726","article-title":"Tumor infiltrating CD8 T lymphocyte count is independent of tumor TLR9 status in treatment naive triple negative breast cancer and renal cell carcinoma","volume":"4","author":"Mella","year":"2015","journal-title":"Oncoimmunology"},{"key":"2022061706163379300_bib8","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1101\/gad.1820209","article-title":"Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression","volume":"23","author":"Gibbons","year":"2009","journal-title":"Genes Dev"},{"key":"2022061706163379300_bib9","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1172\/JCI72171","article-title":"ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism","volume":"124","author":"Yang","year":"2014","journal-title":"J Clin Invest"},{"key":"2022061706163379300_bib10","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1097\/PAS.0b013e3181e4ee32","article-title":"A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors","volume":"34","author":"Sica","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"2022061706163379300_bib11","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/cncr.24831","article-title":"Prognostic significance of grading in lung adenocarcinoma","volume":"116","author":"Barletta","year":"2010","journal-title":"Cancer"},{"key":"2022061706163379300_bib12","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0169-5002(02)00172-1","article-title":"Tumour necrosis is an independent prognostic marker in non-small cell lung cancer: correlation with biological variables","volume":"37","author":"Swinson","year":"2002","journal-title":"Lung Cancer"},{"key":"2022061706163379300_bib13","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1158\/0008-5472.CAN-15-1082","article-title":"A threshold level of intratumor CD8+ T-cell PD1 expression dictates therapeutic response to anti-PD1","volume":"75","author":"Ngiow","year":"2015","journal-title":"Cancer Res"},{"key":"2022061706163379300_bib14","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1158\/2326-6066.CIR-15-0143","article-title":"Reflections on the histopathology of tumor-infiltrating lymphocytes in melanoma and the host immune response","volume":"3","author":"Mihm","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"2022061706163379300_bib15","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/0008-5472.CAN-10-2820","article-title":"The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity","volume":"71","author":"Burnette","year":"2011","journal-title":"Cancer Res"},{"key":"2022061706163379300_bib16","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors","volume":"41","author":"Deng","year":"2014","journal-title":"Immunity"},{"key":"2022061706163379300_bib17","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1182\/blood-2009-02-206870","article-title":"Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment","volume":"114","author":"Lee","year":"2009","journal-title":"Blood"},{"key":"2022061706163379300_bib18","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J Exp Med"},{"key":"2022061706163379300_bib19","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S1470-2045(15)70168-3","article-title":"Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials","volume":"16","author":"Chang","year":"2015","journal-title":"Lancet Oncol"},{"key":"2022061706163379300_bib20","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0074-7696(07)56005-5","article-title":"MHC class I antigens and immune surveillance in transformed cells","volume":"256","author":"Aptsiauri","year":"2007","journal-title":"Int Rev Cytol"},{"key":"2022061706163379300_bib21","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/jnci\/88.2.100","article-title":"Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy","volume":"88","author":"Restifo","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"2022061706163379300_bib22","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1172\/JCI114984","article-title":"Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression","volume":"87","author":"D'Urso","year":"1991","journal-title":"J Clin Invest"},{"key":"2022061706163379300_bib23","doi-asserted-by":"crossref","first-page":"6593","DOI":"10.1158\/1078-0432.CCR-14-0567","article-title":"Genetic evolution of T-cell resistance in the course of melanoma progression","volume":"20","author":"Sucker","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2022061706163379300_bib24","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"2022061706163379300_bib25","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jaci.2014.12.1937","article-title":"\u03b22-Microglobulin deficiency causes a complex immunodeficiency of the innate and adaptive immune system","volume":"136","author":"Ardeniz","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"2022061706163379300_bib26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1677\/erc.0.0060041","article-title":"Induction of cell death by radiotherapy","volume":"6","author":"Ross","year":"1999","journal-title":"Endocr Relat Cancer"},{"key":"2022061706163379300_bib27","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"2022061706163379300_bib28","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"J Clin Invest"},{"key":"2022061706163379300_bib29","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00262-013-1506-7","article-title":"Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8(+) T cells","volume":"63","author":"Lim","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"2022061706163379300_bib30","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nature07423","article-title":"Somatic mutations affect key pathways in lung adenocarcinoma","volume":"455","author":"Ding","year":"2008","journal-title":"Nature"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/77\/4\/839\/2760479\/839.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/77\/4\/839\/2760479\/839.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T13:55:54Z","timestamp":1655474154000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/77\/4\/839\/624088\/Suppression-of-Type-I-IFN-Signaling-in-Tumors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,14]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,2,14]]},"published-print":{"date-parts":[[2017,2,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-15-3142","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6509342.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6509342","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22415648.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22415639.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22415645.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22415642.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22415651","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22415642","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22415645","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22415648","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22415651.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22415639","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,14]]}}}